 By Beth Senko, CFA NASDAQ:EYEG READ THE FULL EYEG RESEARCH REPORT EyeGate Pharmaceuticals NASDAQ:EYEG is a late-stage clinical company developing better solutions to current treatments for post-surgical eye care and moderate to severe dry eye using OBG, its proprietary cross-linked formulation of sodium hyaluronate HA. 2019 was a turning point for EyeGate Pharmaceuticals. In March, 2019, the 